Mike De Vivo

Title: Mike De Vivo: Innovator in Selective PDE4 Inhibition

Introduction

Mike De Vivo is a notable inventor based in New York, NY (US). He has made significant contributions to the field of pharmacology, particularly in the development of selective phosphodiesterase 4 (PDE4) inhibitors. His work has the potential to impact various therapeutic areas, including inflammation and neurodegenerative diseases.

Latest Patents

Mike De Vivo holds a patent for phosphodiesterase 4 inhibitors. This patent describes the selective inhibition of PDE4 achieved through 4-(substituted-phenyl)-2-pyrrolidinone compounds. These compounds demonstrate improved PDE4 inhibition compared to existing compounds like rolipram and exhibit selectivity regarding the inhibition of other classes of PDEs. The compounds of the present invention are defined by a specific formula, wherein R, R, and R are as defined in the patent documentation.

Career Highlights

Mike De Vivo is associated with Memory Pharmaceuticals Corporation, where he has been instrumental in advancing research and development in the pharmaceutical sector. His expertise in PDE4 inhibitors showcases his commitment to innovation in drug development.

Collaborations

Some of his notable coworkers include Ruiping Liu and Hans-Jurgen E Hess. Their collaborative efforts contribute to the ongoing research and development initiatives at Memory Pharmaceuticals Corporation.

Conclusion

Mike De Vivo's work in the field of selective PDE4 inhibition represents a significant advancement in pharmacological research. His contributions are poised to influence future therapeutic strategies and improve patient outcomes.